Cite
HARVARD Citation
Taramasso, L. et al. (2018). First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV medicine. 19 (7), pp. 475-484. [Online].